Specialist biotech venture firm 4BIO Capital has announced two significant leadership appointments to bolster its investment and company-building capabilities. Dr. Therese Liechtenstein has been promoted to Partner, while Dr. Tetsuyuki Maruyama joins as a Venture Partner. These moves are set to strengthen the firm's expertise in developing breakthrough precision therapies for patients.
Strengthening Leadership from Within
Dr. Liechtenstein's promotion to Partner follows her successful tenure as Investment Director since 2024, where she held key board roles. Her elevation recognizes her significant contributions, including leading Actithera’s $75.5 million Series A financing. She also supported Araris Biotech’s acquisition by Taiho Pharmaceutical in a deal valued up to $1.14 billion.
Before joining 4BIO Capital, Dr. Liechtenstein honed her expertise at M Ventures, the corporate venture arm of Merck KGaA. As a Senior Investment Director, she spearheaded company creation efforts and led new investments across Europe and North America. Her prior experience also includes managing strategic projects for Merck’s Healthcare business.
Expanding Global Expertise
The firm is also expanding its global reach with the appointment of Dr. Tetsu Maruyama as Venture Partner based in Japan. Dr. Maruyama brings over two decades of leadership experience in neuroscience and translational drug discovery. He will focus on identifying and transforming innovative Japanese technologies into breakthrough therapies for patients.
Dr. Maruyama's distinguished career includes senior R&D leadership positions at several global pharmaceutical giants. He previously served as Head of Drug Discovery at Takeda Pharmaceuticals and held key roles at Merck and GlaxoSmithKline. His extensive industry background provides him with deep insights into therapeutic development.
Beyond his corporate roles, Dr. Maruyama has a strong background in academia, having held faculty positions in the US and UK. He served as Chief Scientific Officer for the Dementia Discovery Fund and was a member of the World Dementia Council. His credentials include a PhD from Stanford and post-doctoral research at Yale.
A Strategic Vision for Future Growth
Both appointees expressed their enthusiasm for advancing 4BIO Capital's mission. Dr. Liechtenstein affirmed her shared conviction in the firm's thesis of backing strong science and people to overcome biological challenges. She looks forward to continuing her work in guiding portfolio companies toward clinical translation.
Dr. Maruyama highlighted 4BIO’s commitment to tackling complex scientific problems as a key motivator for joining the firm. He intends to leverage his global R&D and neuroscience experience to help founders build scientifically rigorous platforms. His goal is to deliver meaningful therapeutic impact and support innovation in Japan.
Dima Kuzmin, Managing Partner at 4BIO Capital, emphasized the strategic value of these appointments. He praised Dr. Liechtenstein's exceptional conviction while welcoming Dr. Maruyama's deep neuroscience expertise. Kuzmin noted their complementary perspectives will be crucial in accelerating the delivery of life-changing therapies for patients.
These key leadership appointments signal a new phase of strategic growth for 4BIO Capital. By promoting proven internal talent and onboarding world-class external expertise, the firm is reinforcing its position as a leading biotech investor. The additions are poised to enhance its ability to transform scientific innovation into impactful therapies for patients globally.